Ascletis Pharma Stock Market Outlook
| ASCLF Stock | USD 2.10 0.12 6.06% |
Roughly 55% of Ascletis Pharma's stockholders are presently thinking to get in. The analysis of overall sentiment of trading Ascletis Pharma pink sheet suggests that some investors are interested at this time. The current market sentiment, together with Ascletis Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Ascletis Pharma stock news signals to limit their universe of possible portfolio assets.
Comfort Level 55
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Ascletis Pharma's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Ascletis Pharma.
News SentimentNeutral | Hype SentimentBullish | Insider SentimentWaiting |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Ascletis Pharma is 'Cautious Hold'. Macroaxis provides Ascletis Pharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ASCLF positions.
Execute Ascletis Pharma Advice
The Ascletis recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Ascletis Pharma. Macroaxis does not own or have any residual interests in Ascletis Pharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Ascletis Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Fair | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
For the selected time horizon Ascletis Pharma has a Mean Deviation of 3.58, Semi Deviation of 3.63, Standard Deviation of 6.8, Variance of 46.18, Downside Variance of 112.12 and Semi Variance of 13.14We provide trade advice to complement the prevailing expert consensus on Ascletis Pharma. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Ascletis Pharma is not overpriced, please confirm all Ascletis Pharma fundamentals, including its price to sales, cash per share, and the relationship between the shares owned by insiders and ebitda . Please also double-check Ascletis Pharma shares owned by insiders to validate your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.
Ascletis Pharma Trading Alerts and Improvement Suggestions
| Ascletis Pharma is way too risky over 90 days horizon | |
| Ascletis Pharma appears to be risky and price may revert if volatility continues | |
| Ascletis Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 76.88 M. Net Loss for the year was (199.02 M) with profit before overhead, payroll, taxes, and interest of 39.17 M. | |
| Ascletis Pharma has accumulated about 2.5 B in cash with (146.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.28, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 67.0% of the company shares are held by company insiders |
Ascletis Pharma current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ascletis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ascletis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Ascletis Pharma Returns Distribution Density
The distribution of Ascletis Pharma's historical returns is an attempt to chart the uncertainty of Ascletis Pharma's future price movements. The chart of the probability distribution of Ascletis Pharma daily returns describes the distribution of returns around its average expected value. We use Ascletis Pharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Ascletis Pharma returns is essential to provide solid investment analysis for Ascletis Pharma.
| Mean Return | 1.13 | Value At Risk | -4.69 | Potential Upside | 13.14 | Standard Deviation | 6.80 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Ascletis Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Ascletis Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Ascletis Pharma or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Ascletis Pharma's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Ascletis pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 1.08 | |
β | Beta against Dow Jones | 0.47 | |
σ | Overall volatility | 5.59 | |
Ir | Information ratio | 0.15 |
Ascletis Pharma Volatility Alert
Ascletis Pharma is showing large volatility of returns over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Ascletis Pharma's pink sheet risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Ascletis Pharma's pink sheet price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Ascletis Pharma Fundamentals Vs Peers
Comparing Ascletis Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Ascletis Pharma's direct or indirect competition across all of the common fundamentals between Ascletis Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Ascletis Pharma or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Ascletis Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Ascletis Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Ascletis Pharma to competition |
| Fundamentals | Ascletis Pharma | Peer Average |
| Return On Equity | -0.0632 | -0.31 |
| Return On Asset | -0.053 | -0.14 |
| Profit Margin | (2.24) % | (1.27) % |
| Operating Margin | (3.11) % | (5.51) % |
| Current Valuation | 116.15 M | 16.62 B |
| Shares Outstanding | 1.09 B | 571.82 M |
| Shares Owned By Insiders | 67.02 % | 10.09 % |
| Shares Owned By Institutions | 1.94 % | 39.21 % |
| Price To Book | 1.58 X | 9.51 X |
| Price To Sales | 7.61 X | 11.42 X |
| Revenue | 76.88 M | 9.43 B |
| Gross Profit | 39.17 M | 27.38 B |
| EBITDA | (169.35 M) | 3.9 B |
| Net Income | (199.02 M) | 570.98 M |
| Cash And Equivalents | 2.5 B | 2.7 B |
| Cash Per Share | 2.28 X | 5.01 X |
| Total Debt | 2.75 M | 5.32 B |
| Debt To Equity | 0 % | 48.70 % |
| Current Ratio | 28.93 X | 2.16 X |
| Book Value Per Share | 2.50 X | 1.93 K |
| Cash Flow From Operations | (146.93 M) | 971.22 M |
| Earnings Per Share | (0.03) X | 3.12 X |
| Number Of Employees | 315 | 18.84 K |
| Beta | 0.81 | -0.15 |
| Market Capitalization | 672.93 M | 19.03 B |
| Total Asset | 2.83 B | 29.47 B |
| Net Asset | 2.83 B |
Ascletis Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Ascletis . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 1.06 | |||
| Day Median Price | 2.1 | |||
| Day Typical Price | 2.1 | |||
| Price Action Indicator | 0.06 | |||
| Period Momentum Indicator | 0.12 |
About Ascletis Pharma Buy or Sell Advice
When is the right time to buy or sell Ascletis Pharma? Buying financial instruments such as Ascletis Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Ascletis Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cannabis Thematic Idea Now
Cannabis
Equities that are involved in production and delivery of legal cannabis. This theme is designed for investors that are willing to accept higher levels of market risk inherited by cannabis production and distribution globally. The Cannabis theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cannabis Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Ascletis Pink Sheet
Ascletis Pharma financial ratios help investors to determine whether Ascletis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ascletis with respect to the benefits of owning Ascletis Pharma security.